CASP8


Also found in: Dictionary, Thesaurus, Encyclopedia.

CASP8

A gene on chromosome 2q33-q34 that encodes a protein belonging to the cysteine-aspartic acid protease (caspase) family which, once activated by proteolytic processing, plays a central role in the execution phase of cell apoptosis, as well as various stages of embryological development. CASP8 is an initiator-type caspase, which is activated by, and interacts with, upstream adaptor molecules through CARD and DED protein–protein interaction domains; it is involved in the programmed cell death induced by Fas and various apoptotic stimuli. It is highly expressed in peripheral blood leukocytes and in the spleen, thymus and liver.

Molecular pathology
CASP8 has been detected in the insoluble fraction of affected brain regions in Huntington disease, suggesting a role in neurodegenerative diseases.
References in periodicals archive ?
Inhibition of the extrinsic pathway by CASP10 and CASP8 inhibitors prevented apoptosis by up to 75% and 60%, respectively, after treatment with viscum and by 50% and 30%, respectively, in viscumTT-treated cells.
Viscum and viscumTT triggered apoptosis in RMS via the extrinsic as well as the intrinsic apoptosis signalling pathway, evidenced by mitochondrial membrane depolarisation and activation of CASP8 and CASP9 (Figure 7).
Inhibition of the extrinsic pathway by CASP8 and CASP10 inhibitors reduced apoptosis significantly.
Finally, for the apoptosis genes, Casp8 had significantly higher expression in shear compared to axial specimens at d14 (Figure 1(d)).
The genes that have the lowest expression over time for all treatments were Col2a1, Sox9, Comp, and Casp8. The general trend of the temporal changes was similar for all treatments, including the nonimpacted control.
A common coding variant in CASP8 is associated with breast cancer risk.
Breast cancer risk Genes References Rare high-risk genes BRC A1 [1] (x 10-20 lifetime risk) BRC A2 [2] TP53 [4] Rare moderate-risk genes ATM [6] (x 2-4 lifetime risk) BRIP1 [8] CHEK2 [7] PALB2 [9,10] Common low-risk genes FGFR2 [15,18] (x <2 lifetime risk) MAP3K1 [15] TNCR9 [15] LSP1 [15] CASP8* [12] Variants in genes [15,19-21] at chromosomes 6q22.33, 2q35, 16q12 and 5p12 * CASP8 variant is protective.
FasL [0,1] FasL * 0 Casp8 [0,1] Casp8 * 0 Casp3 [0,1] Casp3 * 0 Apop 0 Bid [0,1] tBid 0 DNA [0,1] DNAdamage 0 ATR [0,1] ATR * 0 p53 [0,1] p53 * 0 Bax [0,1] BCl2 [0,1] Cytcmit [0,1] Cytc 0 Casp9 [0,1] Casp9 * 0 granB [0,1] granB * 0 Casp10 [0,1] Casp10 * 0 FasL *.Casp8 0 Casp8 *.Casp3 0 ATR *.p53 0 p53 *.Bax 0 Bax.Bak 0 p53 *.BCl2 0 BCl2.Bax 0 Cytc.Casp9 0 Casp9 *.Casp3 0 granB * .Casp10 0 Casp10 *.Casp3 0 Casp8 *.Bid 0 tBid.Bax 0 granB * .Bid 0 All values are in nondimensional form.
Other genes located in this region, such as Casp8, Icos (induced T-cell costimulator), CD28, and chemokine receptors Cxcrl and Cxcr2 (IL-8receptor) could also be involved in this phenotype by regulating activation of the inflammatory and adaptive immune responses.
Genes evolved in apoptosis like Casp8 maybe implicated in the different resistance pattern we observed.
Antiapoptosis genes such as CASP8 and FADD-like apoptosis regulator (CFLAR) are induced by PAXgene reagent (see Fig.